Piper Jaffray Believes RGNX Won’t Stop Here

By Jason Carr

Piper Jaffray analyst Joshua Schimmer reiterated a Buy rating on RegenXBio (NASDAQ: RGNX) on November 9 and set a price target of $25. The company’s shares closed last Friday at $23.30, close to its 52-week high of $25.

According to TipRanks.com, Schimmer is ranked 0 out of 5 stars with an average return of -3.7% and a 43.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Bellicum Pharmaceuticals, and Voyager Therapeutics Inc.

RegenXBio has an analyst consensus of Moderate Buy.

Based on RegenXBio’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $125K and GAAP net loss of $18.15 million. In comparison, last year the company earned revenue of $1.14 million and had a GAAP net loss of $7.33 million.

REGENXBIO, Inc. is a biotechnology company. It engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills on July 16, 2008 and is headquartered in Rockville, MD.